Regulatory Submissions & Designations
This section covers the regulatory filings and designation pathways that determine whether, and how, an investigational product can enter and progress through clinical testing. Before a sponsor can administer an investigational drug or biologic to human subjects, it must typically obtain authorization from the relevant regulatory authority - in the United States, this takes the form of an Investigational New Drug (IND) application filed with the FDA. Comparable pre-market authorization mechanisms exist in other jurisdictions, including the EMA in Europe, and this cluster covers the categories and logic of these pathways rather than any single agency's forms in isolation. A major organizing standard here is the ICH M4 Common Technical Document (CTD), which defines a harmonized structure for how sponsors organize and present quality, nonclinical, and clinical information across regulatory submissions to ICH member authorities. This harmonization is what allows a single core submission package to be adapted across multiple regulatory jurisdictions rather than rebuilt from scratch for each one. This cluster also covers special regulatory designations that alter a product's development pathway - orphan drug designation being a prominent example, which is granted to products intended to treat rare diseases and typically confers incentives such as extended market exclusivity and, in some jurisdictions, reduced fees or eligibility for expedited review. For a research administrator, this is the area that determines what documentation must exist before enrollment can begin, and what regulatory status a product carries that shapes its trial design, timeline, and reporting obligations.
Guides
JFDA Jordan Clinical Trial Approval Pathway: The Clinical Studies Committee Process
How Jordan’s JFDA and its 12-member Clinical Studies Committee review and approve clinical trials after local IRB approval, including a correction to the 210-day figure that actually applies to drug marketing authorization, not trial approval.
Chile’s ISP/ANAMED Clinical Trial Approval Pathway
How Chile approves clinical trials — the CEC ethics-committee track, ISP/ANAMED’s separate investigational-product authorization, and why a 2025 ISP reliance resolution for biologics registration is a different thing entirely.
Peru Clinical Trial Authorization: INS/OGITT and DIGEMID’s Binding Safety Opinion Process
How Peru’s National Institute of Health (INS) and DIGEMID divide clinical trial authorization: ethics committee review, DIGEMID’s binding technical opinion on investigational product safety, and the INS decision timeline.
Ghana FDA Clinical Trial Authorization: WHO Maturity Level 4 Regulatory Pathway
How Ghana’s Food and Drugs Authority authorizes clinical trials, what its WHO Maturity Level 4 status in Clinical Trials Oversight means for sponsors, and how the CTA process compares to peer African regulators.
NMRA Sri Lanka Clinical Trial Approval Pathway: The Authorization Process
How Sri Lanka’s National Medicines Regulatory Authority (NMRA) authorizes clinical trials, its dual-track structure with Ethics Review Committees, and the mandatory Sri Lanka Clinical Trials Registry (SLCTR) requirement.
Qatar Clinical Trial Approval Pathway: MOPH and the 2026 Executive Regulations
How clinical trial approval works in Qatar under Law No. 6 of 2025 on the regulation of health research and its 2026 executive regulations: the Ministry of Public Health’s research governance function, the new National Committee for Ethics of Health Research, IRBNet-based submission, and what sponsors need to prepare.
Ukraine Clinical Trial Approval Pathway: State Expert Center (SEC) and Parallel Ethics Committee Review
How Ukraine authorizes clinical trials: the State Expert Center’s dossier review running in parallel with independent Local Ethics Committee review, plus the statutory-versus-practical timeline gap sponsors should plan around.
DGDA Clinical Trial Approval Pathway: Bangladesh’s Regulatory Process
How Bangladesh’s Directorate General of Drug Administration (DGDA) and the BMRC’s National Research Ethics Committee jointly authorize clinical trials, including the required sequence of ethics and regulatory review, application documents, and stated timelines.
DRAP Clinical Trial Approval: Pakistan’s Regulatory Pathway
How Pakistan’s Drug Regulatory Authority (DRAP) authorizes clinical trials under the Bio-Study Rules 2017, including the Clinical Studies Committee review, IRB/ERC approval, and the mandatory Clinical Trials Registry.
TFDA Taiwan Clinical Trial Application: IND Process and Multinational CTN Fast Track
How Taiwan’s TFDA and CDE review clinical trial (IND-equivalent) applications, the documented multinational fast-track mechanism for multiregional trials, and what CASRAI could and could not verify about its specific timelines.
New Zealand Clinical Trial Approval: The Medsafe and HRC Pathway
New Zealand requires formal pre-commencement regulatory approval for trials of new medicines, reviewed by Health Research Council committees on Medsafe’s behalf, running in parallel with mandatory HDEC ethics review.
Thailand Clinical Trial Approval: Thai FDA and Ethics Committee Pathway
How Thailand’s dual-track clinical trial approval process works: Thai FDA drug import/production authorization, Thai FDA-recognized Ethics Committee (EC) review via ECMOPH or CREC, and how the two approvals gate each other before a trial can enroll.
Kenya Clinical Trial Authorization: The Pharmacy and Poisons Board (PPB) Approval Pathway
How Kenya’s Pharmacy and Poisons Board authorizes clinical trials, how it fits with NACOSTI’s ethics/research-permit track, and where PPB differs from Kenya’s NRF funding body.
INVIMA Colombia Clinical Trial Approval Pathway: The 2026 Regulatory Picture
How INVIMA approves clinical trials in Colombia — Resolution 2378 of 2008, institutional ethics committees, the no-objection pathway, and what has and hasn’t actually changed for 2026.
Vietnam Clinical Trial Approval: DAV, ASTT, and the Ministry of Health Pathway
Vietnam’s clinical trial approval runs through the Ministry of Health’s ASTT unit and the ethics committee system, not DAV directly — DAV’s role is drug registration and import licensing. Here’s how the two tracks actually fit together.
UAE Clinical Trial Approval Pathway: MOHAP, EDE, and DHA
MOHAP, the new Emirates Drug Establishment, and DHA’s Dubai Scientific Research Ethics Committee: how the UAE’s federal-plus-emirate clinical trial approval pathway actually works, and what the 2024-2025 legal overhaul changed.
NPRA Malaysia Clinical Trial Import Licence (CTIL) and Clinical Trial Exemption (CTX): Approval Process
A guide to Malaysia’s NPRA-administered CTIL and CTX pathways for importing or locally manufacturing investigational products for clinical trials, including IPESS screening, indicative timelines, and how ethics review via MREC fits alongside product authorisation.
Philippines FDA Clinical Trial Application Process: Administrative Order 2020-0010
How the Philippines FDA authorizes clinical trials under Administrative Order 2020-0010: the License to Operate prerequisite, the CTA and Import License applications, REC ethics review, and post-authorization SUSAR and reporting obligations.
BPOM Indonesia Clinical Trial Approval Process: Regulation No. 34 of 2025 Update
BPOM’s clinical trial approval process under Regulation No. 8 of 2024, and what Regulation No. 34 of 2025’s cosmetic-clinical-trial amendment does and doesn’t change.
SFDA Saudi Arabia Clinical Trial Authorization: Pathway and SCTR Registration
How Saudi Arabia’s SFDA authorizes clinical trials, how the Saudi Clinical Trials Registry (SCTR) functions as both application portal and public registry, and what local CRO, personnel, and reporting obligations sponsors need to plan for.
The African Medicines Agency: What It Means for Multi-Country Clinical Trials in Africa
The African Medicines Agency coordinates joint scientific review across African Union member states. Here’s what it actually does today, and what sponsors need to plan for when running multi-country African trials.
ANMAT Clinical Trial Authorization: Argentina’s Regulatory Pathway and the 62-Day Framework
How ANMAT authorizes Phase I-III clinical trials in Argentina, from the 2010-era 90-business-day window through the 2017 reform to the newly effective Disposición 7516/2025 and its ICH E6(R3) adoption.
EDA Clinical Trial Approval: Egypt’s Regulatory Pathway (Routine, Non-Routine, and Reliance Tracks)
How the Egyptian Drug Authority (EDA) evaluates clinical trial applications through its Routine, Non-Routine, and Reliance submission tracks, including the 5-day screening step, decision timelines, one-year approval validity, and the EDA’s new Guideline for Good Regulatory Oversight of Clinical Trials.
NAFDAC Clinical Trial Approval: Nigeria’s Regulatory Pathway and 2025 GCP Guidelines
How NAFDAC’s clinical trial approval, NHREC/institutional ethics clearance, the 2025 GCP Guidelines aligned to ICH E6(R3), PIC/S engagement, and AMRH regional harmonization fit together for a Nigerian trial site.
TITCK Clinical Trial Approval: Turkey’s Regulatory Pathway Explained
How TİTCK, Turkey’s medicines and medical device agency, reviews clinical trial applications alongside Ethics Committees — the EBS submission system, the ~3-4 month timeline, and the new National SUSAR Module effective 15 May 2026.
EMA PRIME Scheme: Priority Medicines Designation, Eligibility, and the 2026 Pilot Features
How EMA’s PRIME scheme works: eligibility criteria, what designation confers, the March 2026 pilot-feature rollout, and 2024 grant-rate statistics.
Clinical Trials in Israel: The Helsinki Committee and Ministry of Health Approval Pathway
How Israel’s decentralized Helsinki Committee system works: local hospital-level review for special trials, Supreme Helsinki Committee review for genetic and ART research, the 2-4 month standard timeline, and Hebrew/Arabic/Russian informed consent requirements.
FDA Platform Technology Designation Program: Eligibility and How It Speeds Manufacturing Changes
FDA’s Platform Technology Designation Program, created by FDORA (2022), lets sponsors designate a well-understood technology — a delivery system, vector, or expression platform — so manufacturing data can be leveraged across products, distinct from FDA’s clinical expedited programs.
FDA Rare Disease Evidence Principles (RDEP): What It Is and What It Means for Sponsors
FDA’s Rare Disease Evidence Principles (RDEP), announced September 2025, clarifies how sponsors of ultra-rare genetic disease drugs can meet the substantial-evidence standard with one pivotal study plus confirmatory evidence such as natural history data, biomarkers, and single-arm trial results.
HSA Clinical Trial Pathways: Singapore’s CTA, CTN, and CTC Framework Explained
Singapore’s HSA runs three distinct clinical trial pathways — CTA, CTN, and CTC — routed by product type and registration status, not trial phase. Here is what triggers each one and how the timelines differ.
Switzerland’s Clinical Trial Regulatory Framework: Swissmedic, HRA, and ClinO
Switzerland authorizes clinical trials through a dual-track system: Swissmedic reviews scientific and product quality while a cantonal ethics committee reviews ethics, in parallel, under the Human Research Act and Clinical Trials Ordinance.
COFEPRIS Clinical Trial Authorization: Mexico’s Regulatory Pathway and the 2025-2026 Reforms
How COFEPRIS authorizes clinical trials in Mexico, and what the 2025-2026 reforms cutting review times from roughly 120 to 30-40 days actually changed.
SAHPRA: South Africa’s Clinical Trial and Bioequivalence Study Authorization Process
SAHPRA authorizes South African clinical trials and bioequivalence studies under Section 21 of the Medicines Act. This guide covers the CTA process, timelines, REC requirements, and generic-drug bioequivalence authorization.
CDSCO Clinical Trial Approval: India’s Regulatory Pathway Explained
How CDSCO and India’s DCGI approve clinical trials under the NDCT Rules 2019: the CT-01/CT-04/CT-06 process, SUGAM portal, 90-working-day timeline, and what the January 2026 amendment actually changed.
MFDS Clinical Trial Approval: South Korea’s IND Pathway
How MFDS reviews Clinical Trial Plan (IND-equivalent) applications in South Korea: the 30-working-day review clock, the Pharmaceutical Affairs Act legal basis, parallel IRB requirements, the pre-CTP consultation fast track, and how it compares to FDA, PMDA, and NMPA.
ANVISA Clinical Trial Approval: Brazil’s Regulatory Pathway Explained
How Brazil’s dual-track clinical trial approval works: ANVISA’s regulatory review, the CEP/CONEP ethics system, RDC 945/2024’s timelines, and where international sponsors lose the most time.
NMPA Clinical Trial Approval Process: China’s Drug Clinical Trial Regulatory Pathway
How China’s NMPA and its Center for Drug Evaluation review and approve drug clinical trial applications: the 60-working-day implicit-approval default, the newer 30-working-day expedited pathway for innovative drugs, the parallel Human Genetic Resources filing, and how it compares to FDA and PMDA.
Real-Time Oncology Review (RTOR): FDA’s Rolling Oncology Submission Process
RTOR lets oncology sponsors submit trial data to FDA on a rolling basis, ahead of the full application, so review can begin earlier. Eligibility, process, and how it differs from Project Orbis, the Assessment Aid, and the classic expedited-program designations.
ICH M11: The New Harmonized Clinical Trial Protocol Template
ICH M11 (CeSHarP) is the new ICH-harmonized clinical trial protocol template and technical specification. Here is its FDA/EMA adoption status and how it relates to TransCelerate’s Common Protocol Template.
Compassionate Use and Expanded Access: FDA Pathways Explained
FDA’s expanded access (“compassionate use”) program lets patients with serious or life-threatening conditions access investigational drugs outside a clinical trial. This guide covers the three expanded-access categories under 21 CFR 312 Subpart I, how expanded access differs from a standard IND application, and how the Right to Try Act works as a separate, parallel pathway.
Canada’s Clinical Trial Regulatory Framework: Health Canada, CTAs, and REB Review
How clinical trials are authorized in Canada: the Health Canada Clinical Trial Application (CTA) process under the Food and Drug Regulations, Research Ethics Board (REB) review under TCPS2, and how this compares to the US FDA/IRB pathway.
FDA 510(k) Premarket Notification: A Guide
A guide to the FDA 510(k) premarket notification pathway: the substantial equivalence standard, device classification (Class I/II/III), how 510(k) differs from PMA and IDE, submission types, and typical review timelines.
FDA Human Factors and Usability Engineering Guidance for Medical Devices
FDA’s human factors and usability engineering guidance requires use-related risk analysis and formative/summative usability testing for medical devices, and explains how it relates to IEC 62366-1 and 510(k)/PMA submissions.
FDA Meeting Types: Type A, B, C, and D Explained
FDA classifies its formal meetings with drug and biologic sponsors into Type A, B, C, and D categories, plus INTERACT — each with its own purpose, timeline, and scope. This guide covers the full taxonomy and how sponsors choose the right meeting type.
FDA AI Guidance: The Regulatory Framework for Artificial Intelligence in Drug Development and Medical Devices
A guide to FDA’s two parallel AI guidance tracks: CDRH’s SaMD AI/ML and PCCP framework for medical devices, and CDER/CBER’s draft guidance on AI in drug and biologic regulatory decision-making, including current draft-vs-final status.
FDA Approval for Gene Therapy: The BLA, CBER, and RMAT Pathway Explained
Gene therapy products are licensed via BLA (not approved via NDA), reviewed by CBER (not CDER), and often pursue RMAT designation. Here’s how the pathway actually works.
FDA Diversity Action Plans for Clinical Trials: Requirements and Status
FDORA requires sponsors of pivotal drug and certain device trials to submit an FDA Diversity Action Plan with enrollment goals by age, sex, race, and ethnicity. What the law requires, which studies are covered, and the current, still-unsettled status of FDA’s implementing guidance.
FDA Guidance on Biocompatibility: ISO 10993 Explained
How FDA’s biocompatibility guidance applies ISO 10993-1’s risk-based framework to 510(k), PMA, De Novo, IDE, and HDE submissions, including the 2023 intact-skin update.
Clinical Trial Disclosure Services: What They Do and Why Sponsors Use Them
Clinical trial disclosure services are vendors and consultancies sponsors hire to manage registry submissions, plain-language summaries, translation, and Clinical Study Report redaction across multiple jurisdictions.
FDA Expedited Programs: Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review Compared
A landscape overview of FDA’s four expedited programs — Fast Track, Breakthrough Therapy designation, Accelerated Approval, and Priority Review — how their eligibility criteria differ, and whether a single drug can hold more than one at once.
FDA Complete Response Letter (CRL): What It Means and What Happens Next
A Complete Response Letter (CRL) is the FDA action issued when a marketing application cannot be approved as submitted — distinct from both an approval and a Refuse-to-File letter.
UK Clinical Trials Regulations: The 2026 Reform, Explained
A summary of the reformed UK clinical trials regulatory regime that took effect 28 April 2026 under SI 2025/538 — risk-proportionate review, combined MHRA/REC assessment, Route B modifications, and new mandatory registration/results-transparency duties.
FDA Form 1571: IND Application Cover Sheet, Purpose, and How to Complete It
Form FDA 1571 is the mandatory cover sheet for every IND submission to FDA — not just the first one. Here’s what it covers, who signs it, how serial numbering works, and how it relates to the substantive 21 CFR 312.23 content requirements.
FDA Breakthrough Therapy Designation: Criteria and Process
How FDA Breakthrough Therapy designation works: the serious-condition and preliminary-clinical-evidence criteria, what the designation confers (intensive guidance, organizational commitment, rolling review), and how it differs from orphan drug designation, Fast Track, Priority Review, and Accelerated Approval.
FDA Medical Device Regulations: Classification, 510(k), and PMA Pathways
A guide to the FDA medical device regulatory framework: risk-based device classification (Class I/II/III), the 510(k) substantial-equivalence pathway, Premarket Approval (PMA), and De Novo classification.
Right to Try Act: Federal Law, Eligibility, and How It Differs From Expanded Access
The federal Right to Try Act (2018) lets certain terminally ill patients obtain unapproved investigational drugs without FDA or IRB sign-off on the individual request. This guide covers patient and drug eligibility, sponsor reporting duties, and how the pathway differs from FDA’s Expanded Access program.
FDA Pre-IND Meeting: Process, Timeline, and Briefing Package
What a pre-IND meeting is, how it is classified as a Type B meeting under 21 CFR 312.82, how to request one, what the briefing package must contain, and the full timeline from request to FDA meeting minutes.
Orphan Drug Designation: FDA Criteria, Process, and Incentives
A practical explainer on FDA orphan drug designation: the prevalence and scientific-rationale criteria, how sponsors apply through the Office of Orphan Products Development, and the incentives designation confers — distinct from orphan drug exclusivity, which only attaches at approval.
